Blog

Testosterone & Anti-Aging Therapy

Sterile & Non-Sterile Compounding

Clinical Laboratory Analysis

Dietary Supplements & Nutraceuticals

Consulting Services

Anti-Aging News

Testosterone Optimization Therapy (TOT) and Fertility Can Coexist
In the constantly evolving landscape of male hormone optimization, few clinical challenges are as delicate as maintaining fertility while undergoing testosterone optimization therapy (TOT). Conventional wisdom and physiology tell us that exogenous testosterone...
Read More
FDA’s Shift on Testosterone: A Long-Awaited Reversal
The U.S. Food and Drug Administration (FDA) has once again reversed course on a major drug safety issue—this time, on testosterone therapy. In response to findings from the TRAVERSE clinical trial and post market ambulatory blood pressure (ABPM) studies, the FDA is...
Read More
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications effective 15 November 2024.  When Covid began the DEA needed to find a solution to allow patients access to care...
Read More
Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list.  The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
Read More
Testosterone Optimization Therapy (TOT) and Fertility Can Coexist
In the constantly evolving landscape of male hormone optimization, few clinical challenges are as delicate as maintaining fertility while undergoing testosterone optimization therapy (TOT). Conventional wisdom and physiology tell us that exogenous testosterone...
Read More
FDA’s Shift on Testosterone: A Long-Awaited Reversal
The U.S. Food and Drug Administration (FDA) has once again reversed course on a major drug safety issue—this time, on testosterone therapy. In response to findings from the TRAVERSE clinical trial and post market ambulatory blood pressure (ABPM) studies, the FDA is...
Read More
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications effective 15 November 2024.  When Covid began the DEA needed to find a solution to allow patients access to care...
Read More
Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list.  The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
Read More